2017 Lecture Series: SAVE THE DATE
Come learn about ABI-LAB's resident companies and have lunch with us!
Save the date: Thursday June 29th, 12-1pm
Join the managing partners, Friday May 19th from 12-1 pm, for lunch and presentations, from Michael Frid from Felicitex and Rick Light from Virtech Bio.
Michael Frid from Felicitex topic is Targeting cancer cell quiescence - Felicitex's approach to the treatment of cancers
Michael Frid is co-founder and VP of pre-clinical at Felicitex Therapeutics Inc, where he is primarily responsible for chemistry, drug candidate characterization and formulation and IP.
Michael has 15+ years of pharmaceutical industry experience, most recently with Wolfe Laboratories, a boutique CRO, where he accumulated extensive experience and expertise in physicochemical characterization and formulation development for a variety of administration routes.
Dr. Frid received his Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology (MIT) and his B.S. in Chemistry Cum Laude from New York University.
Rick Light from Virtech Bio will be: Better preservation through oxygenation.
Company Bio is: VirTech Bio develops innovative therapies for organ and tissue preservation, ex-vivo organ management and biomarker discovery using a technology platform combining machine perfusion (MP) with a new hemoglobin-based oxygen carrier solution (HBOC). Rick Light, VTB CSO, has 30 years of HBOC experience anddeveloped the solution specifically for the ex-vivo market. Previously, he led has R&D, process development, QA, QC and regulatory teams through all aspects of product development including drug development and scale up of bench processes to commercial manufacturing. He received his Ph.D. in Biochemistry from Rice University.